Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zanmira
- Development stage
- Unknown
- Lead developer
- Moberg Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Zanmira is an over-the-counter (OTC) pharmaceutical product primarily used for the treatment of nail disorders, specifically onychomycosis (nail fungus). It was originally part of Moberg Pharma's portfolio and is also known by brand names such as Kerasal Nail, Emtrix, and Nalox in various markets. Following its divestment from Moberg Pharma, Zanmira became part of Advantice Health, a platform established by RoundTable Healthcare Partners and Signet Healthcare Partners, focusing on footcare and first-aid markets.
- Brand names
- ZanmiraKerasal NailEmtrixNalox
Beyond the preview
Go deeper on Zanmira.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zanmira.